Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 13.9% during trading on Thursday . The company traded as high as GBX 4.39 and last traded at GBX 4.10. Approximately 1,246,992 shares traded hands during trading, a decline of 52% from the average daily volume of 2,587,690 shares. The stock had previously closed at GBX 3.60.
ImmuPharma Stock Performance
The company has a market capitalization of £27.39 million, a P/E ratio of -11.86 and a beta of 3.02. The firm’s fifty day moving average is GBX 4.10 and its 200 day moving average is GBX 5.06.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. On average, analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
